Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CONTRAFECT Corp (CFRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 8-K Quarterly results
08/18/2023 8-K Quarterly results
08/14/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update"
07/25/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
03/31/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update"
03/02/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Placement Agency Agreement, between ContraFect Corporation and Maxim Group LLC",
"Form of Pre-Funded Common Stock Purchase Warrant",
"Form of Common Stock Purchase Warrant",
"Opinion of Latham & Watkins LLP",
"Securities Purchase Agreement, by and between ContraFect Corporation and the Purchaser",
"ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement YONKERS, N.Y., Feb 28, 2023 — ContraFect Corporation , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents , including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $10.0 million of its common stock in a registered direct offering and warrants to purchase common stock in a concurrent private placement. The combined effective purchase price for each share of common stock and associated warrants will be $4.00. Under the terms..."
02/14/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Amendments to Articles o...
Docs: "Certificate of Amendment of Amended and Restated Certificate of Incorporation of ContraFect Corporation"
02/02/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
01/26/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
12/19/2022 8-K Quarterly results
12/14/2022 8-K Quarterly results
11/25/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
08/31/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/16/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
07/13/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/24/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"ContraFect Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Update"
11/15/2021 8-K Quarterly results
Docs: "ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
08/13/2021 8-K Quarterly results
05/21/2021 8-K Quarterly results
05/14/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results
03/19/2021 8-K Quarterly results
03/12/2021 8-K Quarterly results
02/12/2021 8-K Quarterly results
11/13/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 13, 2020 ContraFect Corporation Delaware 001-36577 39-2072586 28 Wells Avenue, 3rd Floor, Yonkers, New York 10701 207-2300 Registrant's telephone number, including area code N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commen...",
"ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update"
11/13/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 10, 2020 ContraFect Corporation Delaware 001-36577 39-2072586 28 Wells Avenue, 3rd Floor, Yonkers, New York 10701 207-2300 Registrant's telephone number, including area code N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commen...",
"Amended and Restated Bylaws of ContraFect Corporation, as adopted on November 10, 2020",
"Amended and Restated Bylaws of ContraFect Corporation, as adopted on November 10, 2020, marked to show amendments"
08/14/2020 8-K Quarterly results
06/17/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy